Cortex Pharmaceuticals develops drugs to treat neurodegenerative and psychiatric disorders. Its research focuses on the AMPA receptor, which facilitates communication between nerve cells; the firm's Ampakine compounds may enhance this receptor's activity. Its lead drug candidate is CX717, which it is developing for a number of indications including respiratory depression (a potentially fatal side effect of some anesthetics and post-surgical painkillers), Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), and daytime sleepiness. The firm believes Ampakine drugs may also be helpful in treating a variety of other brain-related disorders, including depression, autism, and Huntington's disease.

Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in the areas of ophthalmology, rheumatology, anesthesia, and antidotes in the United States. The company's Ophthalmic Segment markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, and angiography dyes, which are used in the office setting. It also sells therapeutic products, such as antibiotics, anti-infectives, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers and other national account customers. In addition, this segment offers non-pharmaceutical products, including various artificial tear solutions, preservative-free lubricating ointments, eyelid cleansers, vitamin supplements, and contact lens accessories. The company's Hospital Drugs and Injectables Segment markets specialty injectable pharmaceutical products, including antidotes and anesthesia, as well as products used in the treatment of rheumatoid arthritis and pain management. It markets products to hospitals through wholesalers and other national account customers, as well as directly to medical specialists. The company's Biologics and Vaccines Segment markets adult Tetanus-Diphtheria vaccines directly to hospitals and physicians, as well as through wholesalers and national distributors. Its Contract Services Segment manufactures products for third party pharmaceutical and biotechnology customers. The company also markets and distributes vaccines purchased from outside sources. Its customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, and other pharmaceutical companies.

Alseres Pharmaceuticals, Inc. was founded in 1972 and is headquartered in Hopkinton, Massachusetts. The biotechnology company is developing therapies and diagnostics related to nervous system conditions, such as spinal cord injury, Parkinson's disease, and attention deficit hyperactivity disorder (ADHD). Its lead candidate is Altropane, a molecular imaging agent for diagnosing Parkinson's disease and ADHD. Another candidate, Cethrin, aims to repair nerve damage caused by spinal cord injury; Alseres licensed Cethrin from Canadian firm BioAxone Therapeutic in 2006.

VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment. The Company’s lead compound under development is Xyfid (1% topical uracil) for the treatment and prevention of Hand-Foot Syndrome (HFS). In parallel, Xyfid is also being developed to treat dry skin conditions and manage the burning and itching associated with various diseases of the skin or dermatoses. In addition, VioQuest Pharmaceuticals is developing VQD-002 (triciribine phosphate monohydrate or TCN-P), a small molecule anticancer compound that inhibits activation of protein kinase B (PKB or AKT), a key component of a signaling pathway known to promote cancer cell growth and survival, as well as resistance to chemotherapy and radiotherapy. On July 16, 2007, the Company completed the sale of Chiral Quest, Inc. to Chiral Quest Acquisition Corp.

For biotechnology and pharmaceutical companies whose next big breakthrough is stuck in the test tube, Oxford Therapeutics Consulting could have the answer. The product development consulting firm offers strategic planning and product management for biotechs and pharmas that are short on staff and experience in bringing a new product through the lengthy development pipeline. Oxford Therapeutics' team of consultants work primarily with smaller companies on products such as anticancer agents, antibacterial and antiviral compounds, and therapeutic vaccines.

ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts. ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l.

MicroIslet, Inc. is a biotechnology company engaged in the research, development and commercialization of technologies in the field of transplantation therapy for people with conditions requiring cell-based replacement treatments, with a focus on type 1, or insulin-dependent diabetes. Islet transplantation technology, licensed from Duke University, along with the Company's developments, constitutes methods for isolating, culturing, cryopreservation, and immuno-protection (microencapsulation) of islet cells. MicroIslet intends to continue its research and development efforts and to introduce products to the market.

Johnson & Johnson subsidiary Ortho-McNeil Pharmaceutical, Ortho Dermatologics makes a variety of prescription dermatological potions, including topical creams and injectables used to treat acne, fungal infections, and damage caused by sun exposure and aging. The firm's RETIN-A MICRO ointment, which was developed by AP Pharma, treats acne; and anti-wrinkle cream Renova reduces fine lines brought on by sun exposure. Other products target athlete's foot and promote wound healing.

Founded in 1926, Recordati S.p.A. company makes prescription and nonprescription pharmaceuticals and active pharmaceutical ingredients (APIs). Its prescription drug business includes antibiotics and antiviral drugs, as well as treatments for cardiovascular, central nervous system, dermatological, gynecology, urological, and other disorders and ailments. Over-the-counter products include remedies for allergies and colds, travel sickness, and fungal infections. Recordati company has subsidiaries and direct sales representatives located in about a dozen European countries. Recordati's products are distributed in some 100 countries.

TopoTarget A/S company develops and markets anti-cancer drugs, as well as therapies for cancer-related conditions. Its portfolio includes preclinical candidates, drugs in clinical development, and marketed products. Its Savene therapy is sold in Europe and is a detoxifying drug which limits tissue damage after accidental exposure to certain chemotherapy agents; the drug is also marketed as Totect in the US. Founded in 2000, TopoTarget works with academic and commercial development partners in the US and Europe. Its biopharmaceutical candidates aim to fight cancers such as lymphoma, melanoma, and ovarian, breast, and neck cancers.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.